Related Experiment Video
Updated: Jun 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Effects of diltiazem on postextrasystolic potentiation in coronary heart disease patients
M Di Donato1, M Maioli, N Marchionni
1Cardiology Unit, University of Florence, Italy.
Insights
Diltiazem (D) has a mild negative inotropic effect on the left ventricle (LV) in coronary artery disease patients. However, it maintains postextrasystolic potentiation (PESP) by improving LV loading conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) impacts left ventricular (LV) function.
- Postextrasystolic potentiation (PESP) is a phenomenon reflecting myocardial contractility.
- Calcium antagonists like diltiazem (D) are used in cardiovascular medicine.
Purpose of the Study:
- To investigate the effects of diltiazem (D) on left ventricular (LV) response to postextrasystolic potentiation (PESP) in CAD patients.
- To analyze hemodynamic and LV function parameters under diltiazem.
- To assess regional wall kinetics before and after diltiazem administration.
Main Methods:
- LV angiography was performed in 15 CAD patients.
- Diltiazem (D) was administered (0.25 mg/kg bolus, 1.4 µg/kg/min infusion).
- Programmed atrial stimulation was used to induce PESP, with specific S1-S1, S1-S2, and S2-S3 intervals.
Main Results:
- Diltiazem (D) showed a mild negative inotropic effect, reducing postextrasystolic end-systolic pressure/volume and dP/dtmax.
- The increase in ejection fraction (EF) during PESP was preserved.
- Diltiazem (D) reduced afterload and increased preload (higher EDVI), improving LV filling rate.
Conclusions:
- Diltiazem (D) preserves PESP-induced EF increase by favorably altering LV loading conditions.
- The drug's effects on preload may be due to increased left atrial pressure or improved LV relaxation.
- Diltiazem (D) does not alter overall regional wall kinetics but may be influenced by baseline contraction severity.
Abstract:
The effects of the calcium antagonist, diltiazem (D), on left ventricular (LV) response to postextrasystolic potentiation (PESP) were investigated in 15 coronary artery disease patients. Several haemodynamic and LV function parameters, as well as regional wall kinetics, were analysed. During LV angiography, which was performed before and after D administration (0.25 mg kg-1 bolus and 1.4 microgram kg-1 min-1 infusion), programmed atrial stimulation was applied with the sequence: S1-S1 = 600 ms; S1-S2 = 400 ms; S2-S3 = 800 ms. The results indicate that D exerts a mild negative inotropic effect which is more evident in the postextrasystolic beat (postextrasystolic ESP/ESV and dP/dtmax were significantly lower after D) but the postextrasystolic increase of EF is maintained by the effects of the drug on loading conditions of the left ventricle. Our results indicate that both a reduction of afterload and an increase of preload take place after D. The greater preload reserve induced by the drug (EDVI was significantly higher in each patient after D) was associated with a slight increase in left ventricular filling rate, while end-diastolic compliance and pressure did not show significant variations. These results suggest that the increase in left ventricular preload is due to an increase in left atrial driving pressure, an improvement of left ventricular relaxation or both. D does not affect regional wall kinetics either in basal or in the postextrasystolic beat when overall areas are considered, however its effect seems to be related to the degree of basal regional contraction.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy

